|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0372 - 0.0390|
|52 Week Range||0.0200 - 0.0690|
|Beta (3Y Monthly)||-0.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
EPALINGES, SWITZERLAND / ACCESSWIRE / October 17, 2019 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in Allergen Immunotherapy (AIT), and Anergis, a leader in ultra-fast AIT research and development based on Contiguous Overlapping Peptides (COP), announced the start of a new research study to evaluate the effects of the second generation virosome- based COP allergen immunotherapy in a therapeutic model of birch allergy in mice. The aim is to shorten the AIT administration scheme.
Funding to prepare Mymetics' cold chain-independent needle-free mucosal virosome HIV vaccine candidate for clinical trials Collaboration with Texas Biomedical Institute and University of Louisiana at Lafayette ...
EPALINGES, Switzerland, April 29, 2019 /PRNewswire/ -- Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the National Institutes of Health (NIH) has awarded Mymetics and Texas Biomedical Research Institute (Texas Biomed) a five-year grant for the project called "Cold Chain-independent, Needle-free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels". The project has the objective to prepare Mymetics' promising HIV-1 vaccine candidate for clinical trials.
EPALINGES, SWITZERLAND / ACCESSWIRE / December 13, 2018 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the pre-clinical proof-of-concept study for allergies, with their partner Anergis SA, has met the success criteria. The mice proof-of-concept immunogenicity study evaluated the effects of the Bet v 1 COPs (Anergis' proprietary birch pollen allergy peptides) using the five subcutaneous injection schedule used in former AllerT clinical trials. The development of AllerT (Bet v 1 COPs plus aluminum hydroxide) was discontinued by Anergis in 2017 following completion of a Phase 2 clinical trial showing evidence of sensitization to the peptides and a 7% reduction in seasonal allergy symptoms vs placebo (p=0.0047).
EPALINGES, SWITZERLAND / ACCESSWIRE / November 14, 2018 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life-threatening and life disabling diseases, announces that new data is presented today by Mymetics at the annual Mucosal Vaccines, Adjuvants and Delivery meeting in Lausanne, Switzerland. Since 2015, Mymetics has been leading a consortium to develop thermostable and cold-chain independent virosome-based vaccines. The project, named MACIVIVA, is funded as part of Horizon 2020, the European Union research and innovation framework program and by the Swiss State Secretariat for Education, Research and Innovation (SERI), and has a total grant value of €8.4 million.
EPALINGES, Switzerland, Oct. 30, 2018 /PRNewswire/ -- Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases announces that new data will be presented at the 67th American Society of Tropical Medicine and Hygiene (ASTMH), held from October 28 – November 1, 2018 at in New Orleans, Louisiana. Dr. David L. Narum of the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will discuss the results from an ongoing study in CD-1 mice investigating antibody titer strength, duration and functionality following Pfs230D1M antigen delivered in Mymetics' influenza virosome platform containing a membrane anchored TLR4 and/or TLR7/8 agonist.